ALLG clinical trial NHL30:  PETReA: Phase 3 evaluation of PET-guided, Response-Adapted therapy in patients with previously untreated, high tumour burden follicular lymphoma

Trial Lead: Associate Professor Judith Trotman.

NHL30 is an international Phase III trial.

The study aims to use a [18F]-Fluoro-deoxyglucose (FDG) PET-computed tomography (CT) response-adapted approach, with two randomisations aimed to improve the outcome of patients who remain PET-positive after initial immunochemotherapy, who have been demonstrated to have a very poor outcome, (a superiority study), and to minimise further treatment for good prognosis patients who become PET-negative (a non-inferiority study).  In addition, a comprehensive set of correlative samples will be collected to define immunologic biomarkers of response to treatment.

The clinical trial will recruit approximately 37 patients across 6 Australasian sites. The timeline for the recruitment of patients is 2018 to 2023.

For more information on current clinical trials, visit the ALLG website.